Search Results 1721-1730 of 19694 for Hemoglobin

1. A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) - Mayo Clinic

   Participant has diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) ≥ 50% predicted and/or forced expiratory volume in 1 ...

2. CSF1R And TAM Receptor Inhibition With Q702 - Mayo Clinic

   Hemoglobin ≥8.0 g/dL · Absolute neutrophil count (ANC) ≥1.0 x 109/L · Platelet count ≥80 x 109/L · WBC ≥2.5 x 109/L · Total bilirubin ≤1.5 x ULN · Alanine ...

3. Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer - Mayo Clinic

   Hemoglobin > 9.0 g/dL; Total bilirubin =< 1.5 x upper limit of normal (ULN); if patient has known Gilbert's syndrome, direct bilirubin =< 2.0 x ULN; Aspartate ...

4. Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Mayo Clinic

   Hemoglobin >= 10 g/dL; Platelets >= 100,000/mcL; Total bilirubin =< 1.5 x the institutional upper limit of normal (ULN); Aspartate aminotransferase (AST) ...

5. Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery - Mayo Clinic

   Hemoglobin (Hgb) ≥9 g/dl without transfusion or epoetin dependency (≤7 days prior to assessment);; Absolute neutrophil count ³1.5 x 109/L;; Platelets ≥100 ...

6. A Study of Investigational Immunotherapy to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, with or without Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

   Hemoglobin ≥ 8 g/dL. No transfusions are allowed within 72 hours prior to qualifying laboratory value. Recombinant human erythropoietin not permitted ...

7. Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer - Mayo Clinic

   Hemoglobin (Hgb) ≥ 9 g/dL (obtained ≤ 14 days prior to registration);. NOTE: Packed red blood transfusion is allowed to achieve this parameter as per ...

8. A Study to Evaluate AL102 to Treat Patients with Progressing Desmoid Tumors - Mayo Clinic

   Hemoglobin \<9 g/dL, 4. Total bilirubin \>1.5x upper limit of normal (ULN) (except known Gilbert's syndrome), 5. Aspartate aminotransferase (AST) and ...

9. A Study To Assess The Safety, Tolerability, And Pharmacokinetics Of ABSK-011 In Patients With Advanced Solid Tumor - Mayo Clinic

   Hemoglobin (Hb) ≥80 g/L. Total bilirubin (TBIL) ≤1.5×ULN. Aspartate transaminase (AST) and alanine transaminase (ALT), ≤3×ULN (for patient with liver ...

10. A Study to Evaluate At Home Administration of Pertuzumab Combined with Trastuzumab to Treat Patients with HER2-Positive Breast Cancer During COVID-19 Pandemic - Mayo Clinic

    Hemoglobin < 9 g/dL. Impaired liver function, defined by any of: Serum (total) bilirubin > 1.25 x upper limit of normal (ULN). In case of Gilbert's syndrome ...